Novartis, the Swiss pharmaceuticals giant, is projecting robust growth in its annual sales, expecting an increase of at least 5% per year through 2028, according to CEO Vas Narasimhan. In an interview, he expressed confidence that the company can sustain this growth trajectory despite the impending loss of patent protection for certain drugs. Narasimhan highlighted...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
